Skip navigation
Home
Senate
Assembly
Committees
Service Agencies
Docs
Options
Help
2023 Biennium
Statutes
Admin. Rules
Indices
Miscellaneous
Archives
Home
Bill, Rule, and Appointment Histories
Senators
Representatives
Committees
Text of Introduced Proposals
Amendment Text
Acts
Veto Messages
Enrolled Bills
Drafting Files
Votes
Assembly and Senate Floor Calendars
Schedule of Committee Activities
Assembly and Senate Journals
Committee Records (ROCPs)
Legislative Rules
All Session-Related Documents
Subject Index to Acts
Subject Index to Legislation
Subject Index to Journals
Author Index to Legislation
Subject Index to Clearinghouse Rules
Miscellaneous Budget Documents
Executive Orders
Rulings of the Chair
Wisconsin Supreme Court Rules
Opinions of the Attorney General
Town Law Forms
Law
Districts
Session
Drafting Files
Feeds
Preferences
Show tree
Hide tree
Feedback
Help
Home
Senate Home
Senators
Committees
Session
Chief Clerk
Sergeant at Arms
Civic Education
Human Resources
Assembly Home
Representatives
Committees
Session
Chief Clerk
Sergeant at Arms
Human Resources
Schedule
Joint
Senate
Assembly
Study
Legislative Audit Bureau
Legislative Council
Legislative Fiscal Bureau
Legislative Human Resources Office
Legislative Reference Bureau
Legislative Technology Services Bureau
Menu
»
Administrative Rules Related
»
Clearinghouse Rules
»
Clearinghouse Rules
Controlled Substances Board (CSB)
Stop grouping
[
View All
]
Name
Relating Clause
CR 24-060
(
Text
)
Relating to mail delivered prescriptions.
CR 24-059
(
Text
)
Relating to scheduling nine fentanyl-related substances.
CR 24-058
(
Text
)
Relating to scheduling Zuranolone.
CR 24-048
(
Text
)
Relating to transferring Flualprazolam and scheduling four (4) synthetic benzodiazepine substances.
CR 24-033
(
Text
)
Relating to monitored prescription drug history reports.
CR 24-024
(
Text
)
Relating to excluding Fenfluramine.
CR 24-023
(
Text
)
Relating to scheduling Methiopropamine.
CR 24-013
(
Text
)
Relating to national provider identifier requirement.
CR 24-005
(
Text
)
Relating to scheduling Mesocarb.
CR 24-004
(
Text
)
Relating to excluding [18 F]FP-CIT.
CR 23-069
(
Text
)
Relating to scheduling Zipeprol.
CR 23-068
(
Text
)
Relating to scheduling Amineptine.
CR 23-021
(
Text
)
Relating to scheduling Ganaxolone.
CR 23-020
(
Text
)
Relating to scheduling seven (7) synthetic benzimidazole-opioid substances.
CR 23-019
(
Text
)
Relating to scheduling Daridorexant.
CR 23-018
(
Text
)
Relating to scheduling thirty-eight (38) anabolic steroids.
CR 22-054
(
Text
)
Relating to 4,4’-Dimethylaminorex.
CR 22-040
(
Text
)
Relating to transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP.
CR 22-039
(
Text
)
Relating to scheduling Lacosamide.
CR 22-038
(
Text
)
Relating to scheduling Perampanel.
CR 22-037
(
Text
)
Relating to scheduling Embutramide.
CR 22-036
(
Text
)
Relating to scheduling Fospropofol.
CR 22-035
(
Text
)
Relating to Excluding 6-beta-Naltrexol.
CR 22-034
(
Text
)
Relating to scheduling Alfaxalone.
CR 22-033
(
Text
)
Relating to scheduling ten (10) fentanyl related substances.
CR 22-032
(
Text
)
Relating to scheduling Serdexmethylphenidate.
CR 22-016
(
Text
)
Relating to scheduling Brorphine.
CR 22-014
(
Text
)
Relating to scheduling Remimazolam.
CR 22-011
(
Text
)
Relating to scheduling Crotonyl Fentanyl.
CR 21-098
(
Text
)
Relating to scheduling oliceridine.
CR 20-080
(
Text
)
Relating to designating Gabapentin as a monitored drug having a substantial potential for abuse.
CR 20-079
(
Text
)
Relating to scheduling flualprazolam.
CR 20-078
(
Text
)
Relating to scheduling of norfentanyl.
CR 20-077
(
Text
)
Relating to removing FDA approved cannabidiol from schedule V and excluding FDA approved cannabidiol from schedule I.
CR 20-076
(
Text
)
Relating to scheduling of lemborexant.
CR 20-075
(
Text
)
Relating to scheduling of cenobamate.
CR 20-058
(
Text
)
Relating to scheduling of Lasmiditan.
CR 20-051
(
Text
)
Relating to scheduling of noroxymorphone.
CR 20-050
(
Text
)
Relating to scheduling of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP.
CR 20-049
(
Text
)
Relating to scheduling of brexanolone and solriamfetol.
CR 20-048
(
Text
)
Relating to scheduling of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144.
CR 20-023
(
Text
)
Relating to scheduling isotonitazene and 1P-LSD.
CR 20-022
(
Text
)
Relating to scheduling MMB-FUBICA and 4F-MDMB-BINACA.
CR 19-157
(
Text
)
Relating to special use authorizations.
CR 19-156
(
Text
)
Relating to operation of prescription drug monitoring program.
CR 19-012
(
Text
)
Relating to scheduling FDA approved cannabidiol.
CR 19-011
(
Text
)
Relating to scheduling n-ethylpentylone.
CR 19-010
(
Text
)
Relating to scheduling of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA.
CR 18-070
(
Text
)
Relating to scheduling para-chloroisobutyryl fentanyl.
CR 18-069
(
Text
)
Relating to scheduling of MT-45.
CR 18-055
(
Text
)
Relating to scheduling of oral solutions containing dronabinol.
CR 18-024
(
Text
)
Relating to excluding from scheduling naldemine.
CR 18-023
(
Text
)
Relating to scheduling of ortho-fluorofentanyl.
CR 18-022
(
Text
)
Relating to scheduling of FUB-AMB.
CR 17-089
(
Text
)
Relating to scheduling 4-Fluoroisobutyryl fentanyl
CR 17-088
(
Text
)
Relating to scheduling 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA, and MDMB-FUBINACA
CR 17-087
(
Text
)
Relating to scheduling 4-MePPP and a-PBP
CR 17-086
(
Text
)
Relating to scheduling MAB-CHMINACA
CR 17-085
(
Text
)
Relating to scheduling of AB-CHMINACA, AB-PINACA, and THJ-2201
CR 17-075
(
Text
)
Relating to scheduling cyclopropyl fentanyl.
CR 17-040
(
Text
)
Relating to scheduling acryl fentanyl.
CR 17-028
(
Text
)
Relating to the operation of the prescription drug monitoring program.
CR 17-023
(
Text
)
Relating to scheduling of AH-7921.
CR 17-022
(
Text
)
Relating to scheduling of eluxadoline.
CR 17-021
(
Text
)
Relating to scheduling of acetyl fentanyl.
CR 17-020
(
Text
)
Relating to scheduling of U-47700.
CR 17-009
(
Text
)
Relating to scheduling of brivaracetam.
CR 17-008
(
Text
)
Relating to scheduling of AB-FUBINACA and ADB-PINACA.
CR 17-007
(
Text
)
Relating to scheduling of thiafentanil.
CR 16-081
(
Text
)
Relating to scheduling of beta-hydroxy thiofentanyl and butyrk fentanyl.
CR 16-060
(
Text
)
Relating to exclusion of [123I] ioflupane.
CR 16-059
(
Text
)
Relating to scheduling furanyl fentanyl.
CR 15-101
(
Text
)
Relating to the operation of the prescription drug monitoring program.
CR 15-083
(
Text
)
Relating to measurement of controlled substances for purposes of special use authorizations.
CR 15-070
(
Text
)
Relating to submission of data to the prescription drug monitoring program.
CR 15-068
(
Text
)
Relating to exclusion of naloxegol.
CR 15-009
(
Text
)
Relating to scheduling Suvorexant as a schedule IV controlled substance.
CR 15-008
(
Text
)
Relating to scheduling tramadol as a schedule IV controlled substance.
CR 15-007
(
Text
)
Relating to rescheduling hydrocodone combination products.
/code/chr/all